Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab

Ipilimumab, the first immune-checkpoint inhibitor extending overall survival (OS) in metastatic melanoma patients, has a survival benefit only in a proportion of patients and the development of reliable predictive biomarkers is still an unmet need. To meet this request, we used a multivariate statis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Damuzzo, V., Solito, S., Pinton, L., Carrozzo, E., Valpione, S., Pigozzo, J., Arboretti Giancristofaro, R., Chiarion-Sileni, V., Mandruzzato, S.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2016
Matèries:
MIATA Compliant Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215225/
https://ncbi.nlm.nih.gov/pubmed/28123888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1249559
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars